antithymocyte globulin

Latest news

Tag

Exploring Low-Dose Antithymocyte Globulin Therapy in Type 1 Diabetes: Real-World Insights Using Modified Quantitative Response of C-Peptide

This article examines real-world data on low-dose antithymocyte globulin in type 1 diabetes, assessing beta-cell function via a novel C-peptide modified quantitative response (mQR). Findings suggest feasibility, safety, and potential clinic

Jul 14, 2026

Hematology-Oncology

Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCT

A Phase 2 study demonstrates that pharmacokinetic model-based ATG dosing significantly enhances CD4+ T-cell reconstitution in patients undergoing CD34+ selected hematopoietic cell transplantation, reaching primary endpoints in 70% of partic

Jan 13, 2026Sign in to read

Diabetes & Endocrinology

Optimizing Antithymocyte Globulin Dose for Preserving Beta-Cell Function in Recent-Onset Type 1 Diabetes: Insights from the MELD-ATG Trial

The MELD-ATG phase 2 trial identifies low-dose antithymocyte globulin as an effective and safe intervention to reduce beta-cell loss in young people with recent-onset type 1 diabetes, highlighting a potential disease-modifying therapy.

Oct 11, 2025